JYNNEOS
Phase 3Biologic
JYNNEOS is one of 14 biologic programs targeting Myocarditis. It is currently in Phase 3.
3
Indications
6
Total Trials
4
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Myocarditis
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Medrol
PfizerPhase 3
JYNNEOS
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Corlanor
AmgenPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Standard Medical Therapy
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Drug Inducing Myocarditis
GGroupe Hospitalier Pitie-Salpetriere
Preclinical
Muromonab-CD3
BBarbara Ann Karmanos Cancer Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myocarditis1 trial
Assessment of Myocarditis After Replication-Deficient Smallpox Immunization
Not yet recruiting·—··NCT05513313·2,350 enrolled
Smallpox1 trial
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo
Active, not recruiting·CCenters for Disease Control and Prevention·Phase 3·NCT02977715·1,600 enrolled
Randomized1 trial
Immunogenicity1 trial
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05512949·229 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JYNNEOS. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details